The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma.
Merrick I. Ross
Consultant or Advisory Role - Amgen
Honoraria - Paradigm Medical Communications
Research Funding - Amgen
Robert Hans Ingemar Andtbacka
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Igor Puzanov
Consultant or Advisory Role - Amgen
Mohammed M. Milhem
No relevant relationships to disclose
Frances A. Collichio
Consultant or Advisory Role - Amgen
Research Funding - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Morphotek; Novartis
Keith A. Delman
Research Funding - Amgen
R Dirk Noyes
No relevant relationships to disclose
Jonathan S. Zager
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Expert Testimony - Gill & Chamas, LLC
Lee D. Cranmer
Consultant or Advisory Role - BioVex
Lynn E. Spitler
Consultant or Advisory Role - BioVex
Eddy C. Hsueh
No relevant relationships to disclose
David W. Ollila
No relevant relationships to disclose
Thomas Amatruda
No relevant relationships to disclose
Lisa Chen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jennifer L. Gansert
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Howard L Kaufman
Consultant or Advisory Role - Amgen